Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

NCT02602600 · Completed

Last updated 2026-05-28

This trial tests whether a medication called glucagon-like peptide-1 can improve blood flow in the small heart vessels of women who experience chest pain but do not have blocked arteries.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 33 people

Who can join Ages 40–75 · female only

Timeline Started 2015-11 · est. completion 2017-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02602600 ↗

Description as written by the study sponsor.

The aim of the present study is to evaluate the effect of treatment with Liraglutide on the coronary microvasculature and angina symptoms, in overweight patients with microvascular dysfunction and angina pectoris but no coronary artery stenosis.

Treatments tested

Liraglutide also known as Victoza Drug

* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks. * Weight maintenance diet for 2 weeks

Main thing measured	Change from baseline in Coronary Flow Reserve
Sponsor	Eva Prescott
Conditions studied	Microvascular Angina
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02602600 ↗